Pure Global AI
NCT05901727Recruiting

DSD Models at Malawi Sentinel Sites (SENTINEL 2-Malawi)

Outcomes of Differentiated Models of Service Delivery for HIV Treatment at Sentinel Sites in Malawi (Sentinel-Malawi)
Boston UniversityClinicalTrials.govother
Study focus
Disease/Condition
HIV
Drug/Device/Intervention
No intervention
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Boston University
Location
Lilongwe, Malawi
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2021
End date
Jun 01, 2026
Enrollment
15520 participants
Primary outcome

Proportion of patient survey participants with HIV viral suppression ≤400 copies/ml at most recent test

Summary

To achieve global goals for the treatment of HIV, many countries are piloting and scaling up
 differentiated service delivery models (DSD). A handful of efforts have been formally
 described and evaluated in the literature; many others are being implemented formally or
 informally under routine care, without a research or evaluation goal. For most countries
 however, we have little evidence on progress and challenges at the facility level-the number
 of patients actually participating in DSD models, health outcomes and non-health outcomes,
 effects on service delivery capacity and clinic efficiency and operations, and costs to
 providers and patients.
 
 AMBIT is a set of data synthesis, data collection, and data analysis activities aimed at
 generating information for near- and long-term decision making and creating an approach and
 platform for ongoing evaluation of differentiated models of HIV treatment delivery. The first
 AMBIT protocol, Gathering Records to Evaluate Antiretroviral Treatment (GREAT, Malawi NHRC
 2376), collects and analyzes comprehensive patient medical record data, allowing us to assess
 the effect of DSD models on patients' clinical outcomes and to evaluate uptake of DSD models
 at scale.
 
 The Sentinel-Malawi study, the second AMBIT protocol, is examining the effect of DSD models
 on patient and provider satisfaction, service delivery capacity and quality, costs to
 patients, and other outcomes for which data are not routinely collected in patient-level
 medical records. The first round of Sentinel-Malawi was conducted in 2021. We are now
 amending the protocol to allow up to two additional annual rounds of data collection, in
 2022-2023. We collected clinic aggregate data, conducted surveys of patients and providers,
 and observed operations at a selected set of 12 Malawian healthcare facilities and their
 affiliated DSD models in Round 1. Round 2 and 3 will collect the same types of data at 12
 facilities in Malawi and will expand the study's research questions to include differentiated
 models of HIV testing and linkage to care. Results are expected to inform Malawian policy
 makers and other local and international stakeholders on the actual implications of DSD
 models for patients, health system operations, and healthcare budgets.

ICD-10 classifications
Human immunodeficiency virus [HIV] diseaseHuman immunodeficiency virus [HIV] disease resulting in other conditionsHIV disease resulting in other viral infectionsUnspecified human immunodeficiency virus [HIV] diseaseHuman immunodeficiency virus [HIV] disease resulting in other specified diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05901727
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05901727 through Pure Global AI's free database. This phase not specified trial is sponsored by Boston University and is currently Recruiting. The study focuses on HIV. Target enrollment is 15520 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.